导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.71% | 3271/4773 |
| 近一周 | -1.35% | 2060/5465 |
| 近一月 | -1.45% | 1158/5421 |
| 近一季 | -0.44% | 1063/5231 |
| 近半年 | -1.46% | 1788/4920 |
| 近一年 | -0.33% | 2817/4394 |
| 近两年 | 35.77% | 2082/2954 |
| 近三年 | 22.82% | 1383/2253 |
| 成立以来 | 65.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.44% 4141/4961 |
6.42% 2831/5312 |
- - |
- - |
| 2025 | 16.18% 2476/4813 |
-0.52% 2282/3635 |
2.94% 1244/4076 |
11.19% 3192/4524 |
2.04% 1101/4813 |
| 2024 | 18.13% 623/3463 |
3.64% 531/2808 |
-0.13% 689/3014 |
17.03% 1286/3129 |
-2.47% 2098/3463 |
| 2023 | -7.20% 899/2656 |
2.45% 1347/2280 |
-4.61% 1219/2385 |
1.88% 269/2515 |
-6.80% 1928/2655 |
| 2022 | -17.32% 576/2207 |
-11.27% 496/1919 |
2.55% 1288/2016 |
-12.73% 768/2113 |
4.11% 589/2208 |
| 2021 | 1.35% 679/1822 |
-2.05% 575/1255 |
3.99% 937/1330 |
-3.46% 640/1466 |
3.07% 478/1822 |
| 2020 | 18.96% 737/1250 |
-8.36% 602/1028 |
14.80% 535/1067 |
7.26% 794/1164 |
5.42% 785/1184 |
| 2019 | 26.03% 585/1092 |
26.10% 426/754 |
-5.48% 472/804 |
0.06% 564/850 |
5.68% 691/918 |
| 2018 | -26.25% 377/834 |
- - |
- - |
- - |
-12.59% 460/691 |
| 2017 | 16.70% 233/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.51% 282/605 |
- - |
- - |
- - |
- - |
| 2015 | 20.25% 115/575 |
- - |
- - |
- - |
- - |
| 2014 | 43.30% 114/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.61% 158/186 |
- - |
- - |
- - |
- - |
| 2012 | 15.36% 11/140 |
- - |
- - |
- - |
- - |
| 2011 | -20.92% 42/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安上证50ETF VS. 长安沪深300非周期A(740101) |